InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-1.8%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
无可用的信号评分。
Explore the full record of transactions filed by Bernard Gilly, 首席执行官. Officer active across 1 company, notably Gensight Biologics S.A.. Aggregated, 1 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €117k. Activity tracked since 7 April 2022. The latest transaction was disclosed on 7 April 2022 (Acquisition). Regulator: AMF. The full history is accessible without signup.
Companies and markets linked to Bernard Gilly
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报1 总计
50,000 股@ €2.3425100.0% 占其流量ActionEuronext ParisISIN FR00131839852022DD835024
标准退出：2022年7月6日 (T+90)
1 条申报中的 1 条
About Bernard Gilly
Bernard Gilly is the Chief Executive Officer of GenSight Biologics S.A. He is responsible for the strategic and operational direction of the company, which focuses on developing treatments for eye diseases. His experience in the biopharmaceutical sector is an asset for GenSight.
